Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Zhang, Chenga; * | Kuo, Ching-Changb | Moghadam, Setareh H.a | Monte, Louisea | Rice, Kenner C.c | Rissman, Robert A.a; *
Affiliations: [a] Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA | [b] NeuroInformatics Center, University of Oregon, Eugene, OR, USA | [c] Chemical Biology Research Branch, National Institutes on Drug Abuse and Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA
Correspondence: [*] Correspondence to: Cheng Zhang and Robert A. Rissman, Department of Neurosciences, UCSD School of Medicine, 9500 Gilman Drive, M/C 0624, La Jolla, CA 92037-0624, USA. Tel.: +1 858 246 0141; Fax: +1 858 246 0139; E-mails: [email protected] (C. Zhang), [email protected] (R.A. Rissman).
Abstract: Reports from Alzheimer's disease (AD) biomarker work have shown a strong link between oxidative stress and AD neuropathology. The nonenzymatic antioxidant, glutathione (GSH), plays a crucial role in defense against reactive oxygen species and maintenance of GSH redox homeostasis. In particular, our previous studies on GSH redox imbalance have implicated oxidative stress induced by excessive reactive oxygen species as a major mediator of AD-like events, with the presence of S-glutathionylated proteins (Pr-SSG) appearing prior to overt AD neuropathology. Furthermore, evidence suggests that oxidative stress may be associated with dysfunction of the hypothalamic-pituitary-adrenal axis, leading to activation of inflammatory pathways and increased production of corticotropin-releasing factor (CRF). Therefore, to investigate whether oxidative insults can be attenuated by reduction of central CRF signaling, we administered the type-1 CRF receptor (CRFR1) selective antagonist, R121919, to AD-transgenic mice beginning in the preclinical/prepathologic period (30-day-old) for 150 days, a timepoint where behavioral impairments and pathologic progression should be measureable. Our results indicate that R121919 treatment can significantly reduce Pr-SSG levels and increase glutathione peroxide activity, suggesting that interference of CRFR1 signaling may be useful as a preventative therapy for combating oxidative stress in AD.
Keywords: Alzheimer's disease, corticotropin-releasing factor-1 receptor (CRFR1), glutathione, glutathione peroxide, glutathione reductase, oxidative stress, oxidized glutathione, R121919, S-glutathionylated protein
DOI: 10.3233/JAD-141722
Journal: Journal of Alzheimer's Disease, vol. 45, no. 2, pp. 639-650, 2015
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]